One of Europe’s leading pharmaceutical services providers has appointed De Facto to help it challenge the dominance of the world’s top three contract manufacturing organisations. Recipharm of Sweden is looking to grow in the region of 20% per year and has appointed De Facto to help build its reputation among its key stakeholders as a leader in the drug development and manufacturing services sector
De Facto has already started an extensive international media outreach programme and secured high profile pieces in influential sector publications. It will also be highlighting Recipharm’s in-house development and formulation expertise through a series of articles and case studies in the technical press.
Commenting on the decision to appoint De Facto, Mark Quick, Vice President Corporate Development, said. “We selected De Facto because of their in-depth knowledge of the pharma manufacturing and outsourcing market and their close links with the trade press. This is already paying dividends in terms of the coverage we have secured and the interest that has been generated in our capabilities.”
De Facto co-founder and Director, Kevin Payne, will lead the account.
End
For more information contact Kevin Payne at De Facto on 020 7861 3838 or visit www.defacto.com
